CD274 and tuberculosis: Among the three FDA-approved PD-L1 inhibitors—durvalumab, atezolizumab, and avelumab—only durvalumab showed a statistically significant signal for TB-AEs (ROR = 7.81, 95% CI: 4.43–13.78), supported by other disproportionality metrics (PRR = 7.80, EBGM05 = 4.67, IC025 = 2.15) (Figure 2, Supplementary Table 3).